The % change from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the % changes shown here, the mean value of the % changes of the cases that could be measured at each time point is calculated. In other words, of the 57 cases with the volume value of baseline, Cycle 3 calculates the mean value of the % change in 39 cases with the volume value at this time, and Cycle 5 calculates the mean value of the % change in 40 cases with the volume value at this time.

The remaining 18 cases are excluded from this calculation because there is no volume value for Cycle 3 and the % change from baseline cannot be calculated. The same applies to the 17 cases of Cycle 5.

For this reason, these values cannot be calculated directly from the volume mean value at each time point shown in the result measurement 2.

A straight line with a total length of 10 cm was prepared. This straight line was defined as "no pain" at the left end and "Worst pain imaginable" at the right end.

The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.

The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).

The units on a scale is "cm".

CA-125 is a glycoprotein antigen recognized by the monoclonal antibody OC125 made against ovarian cancer cell cultures.

Serum CA125 is commonly used as a tumor marker for ovarian cancer, and since it increases at a high rate in endometriosis, it has an aspect of being used as a diagnostic aid for endometriosis.

There are many reports that the normal value of serum CA-125 is 35 U/mL or less.

The test was performed during a non-menstruation period, as serum CA-125 levels are high during the menstrual period.

The dysmenorrhea score is the sum of the dysmenorrhea severity score and the analgesic use score.

The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

A dysmenorrhea severity score is defined as follows. None: Score 0, Rarely interfering with work (study and house work): Score 1, Interfering with work (study and house work) requiring lying down to rest: Score 2, Being confined to bed for 1 day, being unable to work (study and house work): Score 3.

A score for the use of analgesics is defined as follows. None: Score 0, An analgesic was used for a day during the last (or current) menstruation period: Score 1, An analgesic was used for 2 days during the last (or current) menstruation period: Score 2, An analgesic was used for 3 days during the last (or current) menstruation period: Score 3

A straight line with a total length of 10 cm was prepared. This straight line was defined as "no pain" at the left end and "Worst pain imaginable" at the right end.

The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.

The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).

The units on a scale is "cm". The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

A straight line with a total length of 10 cm was prepared. This straight line was defined as "no pain" at the left end and "Worst pain imaginable" at the right end.

The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.

The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).

The change rate from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the difference shown here, the mean value of the difference of the cases that could be measured at each time point is calculated.

In other words, of the 56 cases with baseline serum CA125, cycle 5 can only calculate the difference in 32 cases with serum CA125 at this point.

The mean difference between cycle 5 and baseline in these 32 cases is shown here.

The remaining 24 cases in Baseline are excluded from this calculation because they do not have serum CA125 measurements in Cycle 5.

For this reason, these values cannot be calculated directly from the serum CA125 mean value at each time point shown in the result measurement 7.

The change rate from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the change rate shown here, the mean value of the change rate of the cases that could be measured at each time point is calculated.

In other words, of the 56 cases with baseline serum CA125, cycle 5 can only calculate the change rate in 32 cases with serum CA125 at this point.

The mean change rate between cycle 5 and baseline in these 32 cases is shown here.

The remaining 24 cases in baseline are excluded from this calculation because they do not have serum CA125 measurements in Cycle 5.

For this reason, these values cannot be calculated directly from the serum CA125 mean value at each time point shown in the result measurement 7.

the corresponding data has not been acquired

the corresponding data has not been acquired

In measurement of ovarian chocolate cyst, on a section visualizing the maximum diameter, two radial directions, namely the maximum diameter (D1) and maximum diameter (D2) orthogonal to D1, will be measured. A chocolate cyst of the ovary will be deemed as a spheroid, and its volume will be calculated using the following formula: [(D1 + D2) × 1/2]3 × 0.52 (π = 3.1). If there are two or more chocolate cysts of the ovary, similarly, two radial directions (D1 and D2) of each cyst will be measured. Also, each of their volumes will be calculated in the same manner.

Of the safety analysis set (59 subjects), 57 subjects were included in the "efficacy analysis set," after excluding twe subjects (reason: one subject, use of concomitant medication indicated for endometriosis; one subject, violation of entry criteria).

The absolute change from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the absolute changes shown here, the mean value of the absolute changes of the cases that could be measured at each time point is calculated. In other words, of the 57 cases with the volume value of baseline, Cycle 3 calculates the mean value of the absolute change in 39 cases with the volume value at this time, and Cycle 5 calculates the mean value of the absolute change in 40 cases with the volume value at this time.

The remaining 18 cases are excluded from this calculation because there is no volume value for Cycle 3 and the absolute change from baseline cannot be calculated. The same applies to the 17 cases of Cycle 5.

For this reason, these values cannot be calculated directly from the volume mean value at each time point shown in the result measurement 2.

Of the safety analysis set (59 subjects), 57 subjects were included in the "efficacy analysis set," after excluding twe subjects (reason: one subject, use of concomitant medication indicated for endometriosis; one subject, violation of entry criteria).

The % change from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the % changes shown here, the mean value of the % changes of the cases that could be measured at each time point is calculated. In other words, of the 57 cases with the volume value of baseline, Cycle 3 calculates the mean value of the % change in 39 cases with the volume value at this time, and Cycle 5 calculates the mean value of the % change in 40 cases with the volume value at this time.

The remaining 18 cases are excluded from this calculation because there is no volume value for Cycle 3 and the % change from baseline cannot be calculated. The same applies to the 17 cases of Cycle 5.

For this reason, these values cannot be calculated directly from the volume mean value at each time point shown in the result measurement 2.

Of the safety analysis set (59 subjects), 57 subjects were included in the "efficacy analysis set," after excluding twe subjects (reason: one subject, use of concomitant medication indicated for endometriosis; one subject, violation of entry criteria).

The dysmenorrhea score is the sum of the dysmenorrhea severity score and the analgesic use score. Shown as the mean value for the number of cases at each time point.

A dysmenorrhea severity score is defined as follows. None: Score 0, Rarely interfering with work (study and house work): Score 1, Interfering with work (study and house work) requiring lying down to rest: Score 2, Being confined to bed for 1 day, being unable to work (study and house work): Score 3.

A analgesic use score is defined as follows. None: Score 0, An analgesic was used for a day during the last (or current) menstruation period: Score 1, An analgesic was used for 2 days during the last (or current) menstruation period: Score 2, An analgesic was used for 3 days during the last (or current) menstruation period: Score 3 The minimum dysmenorrhea score is 0 and the maximum dysmenorrhea score is 6.

A straight line with a total length of 10 cm was prepared. This straight line was defined as "no pain" at the left end and "Worst pain imaginable" at the right end.

The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.

The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).

The units on a scale is "cm".

CA-125 is a glycoprotein antigen recognized by the monoclonal antibody OC125 made against ovarian cancer cell cultures.

Serum CA125 is commonly used as a tumor marker for ovarian cancer, and since it increases at a high rate in endometriosis, it has an aspect of being used as a diagnostic aid for endometriosis.

There are many reports that the normal value of serum CA-125 is 35 U/mL or less.

The test was performed during a non-menstruation period, as serum CA-125 levels are high during the menstrual period.

The dysmenorrhea score is the sum of the dysmenorrhea severity score and the analgesic use score.

The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

A dysmenorrhea severity score is defined as follows. None: Score 0, Rarely interfering with work (study and house work): Score 1, Interfering with work (study and house work) requiring lying down to rest: Score 2, Being confined to bed for 1 day, being unable to work (study and house work): Score 3.

A score for the use of analgesics is defined as follows. None: Score 0, An analgesic was used for a day during the last (or current) menstruation period: Score 1, An analgesic was used for 2 days during the last (or current) menstruation period: Score 2, An analgesic was used for 3 days during the last (or current) menstruation period: Score 3

A straight line with a total length of 10 cm was prepared. This straight line was defined as "no pain" at the left end and "Worst pain imaginable" at the right end.

The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.

The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).

The units on a scale is "cm". The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

One patient had a pain score at Cycle 1 but did not have a pain score at baseline and the absolute change could not be calculated in this instance

A straight line with a total length of 10 cm was prepared. This straight line was defined as "no pain" at the left end and "Worst pain imaginable" at the right end.

The cases marked the degree of pain on this straight line at each time point, and the length (cm) from the left end of the line (0) was measured.

The minimum value of VAS is 0 cm (no pain) and the maximum value is 10 cm (Worst pain imaginable).

The change rate from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

A number of patients at each timepoint had pain scores of "zero" or discontinued treatment and a % change could not be calculated in these instances

The difference from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the difference shown here, the mean value of the difference of the cases that could be measured at each time point is calculated.

In other words, of the 56 cases with baseline serum CA125, cycle 5 can only calculate the difference in 32 cases with serum CA125 at this point.

The mean difference between cycle 5 and baseline in these 32 cases is shown here.

The remaining 24 cases in Baseline are excluded from this calculation because they do not have serum CA125 measurements in Cycle 5.

For this reason, these values cannot be calculated directly from the serum CA125 mean value at each time point shown in the result measurement 7.

The change rate from baseline were calculated on an individual basis and these were totalled and means ± SD calculated.

For the mean value of the change rate shown here, the mean value of the change rate of the cases that could be measured at each time point is calculated.

In other words, of the 56 cases with baseline serum CA125, cycle 5 can only calculate the change rate in 32 cases with serum CA125 at this point.

The mean change rate between cycle 5 and baseline in these 32 cases is shown here.

The remaining 24 cases in baseline are excluded from this calculation because they do not have serum CA125 measurements in Cycle 5.

For this reason, these values cannot be calculated directly from the serum CA125 mean value at each time point shown in the result measurement 7.

The score value and difference from the value before treatment were calculated at the same points using the summary statistics, and the Wilcoxon signed-rank test was performed.

The score value and difference from the value before treatment were calculated at the same points using the summary statistics, and the Wilcoxon signed-rank test was performed.

The score value and difference from the value before treatment were calculated at the same points using the summary statistics, and the Wilcoxon signed-rank test was performed.

The difference from the value before treatment and change rate were calculated using the summary statistics at each observation point and last observation, and the Wilcoxon signed-rank test was performed for the difference and change rate.

The difference from the value before treatment and change rate were calculated using the summary statistics at each observation point and last observation, and the Wilcoxon signed-rank test was performed for the difference and change rate.

The difference from the value before treatment and change rate were calculated using the summary statistics at each observation point and last observation, and the Wilcoxon signed-rank test was performed for the difference and change rate.

The difference from the value before treatment and change rate were calculated using the summary statistics at each observation point and last observation, and the Wilcoxon signed-rank test was performed for the difference and change rate.

The difference from the value before treatment and change rate were calculated using the summary statistics at each observation point and last observation, and the Wilcoxon signed-rank test was performed for the difference and change rate.

The difference from the value before treatment and change rate were calculated using the summary statistics at each observation point and last observation, and the Wilcoxon signed-rank test was performed for the difference and change rate.